$630 Million is the total value of Fairmount Funds Management LLC's 16 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 48.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | Buy | AXSOME THERAPEUTICS INC | $155,158,333 | +83.3% | 2,011,647 | +6.1% | 24.61% | +65.5% |
| Buy | NUVALENT INC | $83,055,854 | +105.4% | 2,788,981 | +34.1% | 13.18% | +85.4% | |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $75,137,494 | +174.4% | 2,875,526 | +7.3% | 11.92% | +147.7% |
| BGNE | Buy | BEIGENE LTDsponsored adr | $52,663,093 | +352.1% | 239,443 | +177.1% | 8.35% | +308.1% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $40,006,688 | +42.4% | 1,369,623 | 0.0% | 6.35% | +28.5% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $33,801,520 | +12.5% | 283,000 | 0.0% | 5.36% | +1.5% | |
| COGT | COGENT BIOSCIENCES INC | $31,893,751 | -22.5% | 2,758,975 | 0.0% | 5.06% | -30.1% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $29,194,868 | -8.9% | 2,543,107 | 0.0% | 4.63% | -17.8% | |
| Buy | ASTRIA THERAPEUTICS INC | $28,311,801 | +243.5% | 1,901,397 | +108.5% | 4.49% | +209.9% | |
| ARGX | ARGENX SEsponsored adr | $27,853,855 | +7.3% | 73,526 | 0.0% | 4.42% | -3.2% | |
| TERN | Sell | TERNS PHARMACEUTICALS INC | $20,767,200 | +72.0% | 2,040,000 | -0.5% | 3.29% | +55.2% |
| ANNX | ANNEXON INC | $17,363,771 | -16.3% | 3,358,563 | 0.0% | 2.76% | -24.5% | |
| TRVI | TREVI THERAPEUTICS INC | $10,994,274 | +25.3% | 5,696,515 | 0.0% | 1.74% | +13.1% | |
| DBVT | DBV TECHNOLOGIES SAsponsored adr | $10,809,395 | -13.6% | 7,064,964 | 0.0% | 1.72% | -22.0% | |
| TYRA BIOSCIENCES INC | $10,769,185 | -13.5% | 1,416,998 | 0.0% | 1.71% | -22.0% | ||
| IMRA | New | IMARA INC | $2,582,152 | – | 631,333 | +100.0% | 0.41% | – |
| ALLK | Exit | ALLAKOS INC | $0 | – | -147,189 | -100.0% | -0.16% | – |
| TIL | Exit | INSTIL BIO INC | $0 | – | -673,905 | -100.0% | -0.57% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS INC | $0 | – | -1,231,566 | -100.0% | -0.60% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -389,588 | -100.0% | -0.66% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -5,584,837 | -100.0% | -1.07% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -272,498 | -100.0% | -1.80% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -751,804 | -100.0% | -2.16% | – |
| PNT | Exit | POINT BIOPHARMA GLOBAL INC | $0 | – | -2,833,950 | -100.0% | -3.85% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -469,264 | -100.0% | -4.28% | – |
| Exit | AXSOME THERAPEUTICS INCcall | $0 | – | -600,000 | -100.0% | -4.71% | – | |
| INSM | Exit | INSMED INC | $0 | – | -1,336,368 | -100.0% | -5.06% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO | $0 | – | -204,743 | -100.0% | -5.44% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.